Pot Stocks To Invest In This 2015

GW Pharmaceuticals’ only approved cannabinoid drug, Sativex, has been launched in 15 countries and approved in 12 others (mainly in Europe) for the treatment of severe spasticity caused by multiple sclerosis. Last year, Sativex revenue doubled year-over-year to 4.4 million pounds ($6.65 million), accounting for nearly 15% of GW’s top line. The remainder of GW’s revenue comes from license fees and milestone payments. Most of those fees come from Otsuka , GW’s Japanese marketing partner, which is trying to get Sativex approved in the United States.

Others come from Novartis , Ipsen Biopharm , Neopharm Group , Almirall , and Bayer , which hold global marketing agreements for Sativex. Looking ahead, another promising drug is Epidiolex, GW’s drug for two kinds of treatment-resistant epilepsy — Dravet and Lennox-Gastaut Syndrome. The drug is currently in a phase 2/3 trial for the Dravet indication, and additional phase 3 trials for both indications will commence in the first quarter of this year.

Make no mistake — GW is a highly speculative biotech that is heavily dependent on a single drug. However, rising sales of Sativex, potentially positive developments regarding Epidiolex, and support from top pharmaceutical companies suggest that the stock might still have room to run.

To read more, visit http://www.nasdaq.com/article/are-there-any-marijuana-stocks-to-buy-in-2015-cm433606

Posted in: Investing

Comments are closed.